HSBC/CALL/PFIZER INC/65/0.1/19.06.24 Stock

Warrant

DE000HG4B4Q9

Real-time BOERSE MUENCHEN 15:37:28 2024-05-31 EDT
0.011 EUR -.--% Intraday chart for HSBC/CALL/PFIZER INC/65/0.1/19.06.24
Date Price Change
24-05-31 0.011 -.--%
24-05-30 0.011 -.--%
24-05-29 0.011 -.--%
24-05-28 0.011 -.--%
24-05-27 0.011 -.--%

Real-time BOERSE MUENCHEN

Last update May 31, 2024 at 03:37 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying PFIZER, INC.
Issuer HSBC
WKN HG4B4Q
ISINDE000HG4B4Q9
Date issued 2022-06-23
Strike 65 $
Maturity 2024-06-20 (18 Days)
Parity 10 : 1
Emission price 0.3
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.47
Lowest since issue 0.011
Delta0.02x
Omega 8.410
Premium128.78x
Gearing437.04x
Moneyness 0.4375
Difference Strike 36.34 $
Difference Strike %+55.91%
Spread 0.01
Spread %90.91%
Theoretical value 0.006000
Implied Volatility 154.83 %
Total Loss Probability 99.25 %
Intrinsic value 0.000000
Present value 0.006000
Break even 65.07 €
Theta-0.01x
Vega0x
Rho0x

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
-
More about the company

Ratings for Pfizer, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Pfizer, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.66 USD
Average target price
31.92 USD
Spread / Average Target
+11.36%
Consensus